Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration.

The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...

Basel: Novartis has received approval from the US Food and Drug Administration (FDA) for Itvisma (onasemnogene ...

I used to have a crate here for JC. For the first two months [after his death], I would carry this pillow and stay in the ...

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...

The apex court asks comedians to host events showcasing success stories of differently-abled citizens while urging the Centre ...

A growing number of 20-somethings are trying to freeze time with preventive Botox treatments. Here's what's behind the trend.

Novartis today announced that the US Food and Drug Administration (FDA) has approved Itvisma® (onasemnogene abeparvovec-brve) for the treatment of children two years and older, teens, and adults ...

ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection. What is the ...

The Centre informed the Supreme Court that it is in the final stages of putting together a regulatory framework for keeping a check on explicit and harmful content on social media platforms.

Novartis ( NVS) on Monday said that the U.S. FDA has approved Itvisma for the treatment of children two years and older, ...

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...